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aims:
Heart failure (HF) is a common manifestation of patients with primary and 
secondary causes of iron overload, whereas in patients with established 
HF iron deficiency impairs outcome. Whether body iron, either depleted or 
in overload, amplifies the risk for new onset HF among healthy individuals 
is unknown. The present study aimed to assess whether markers of iron 
status, or iron-regulatory hormone hepcidin are associated with new onset 
HF or cardiovascular (CV) events in the general population.
methods and results:
In 6386 subjects from the Prevention of REnal and Vascular ENd-stage 
Disease (PREVEND), a prospective, community-based, cohort study, mark-
ers of iron status and iron-regulatory hormone hepcidin were measured. 
Mean age was 53.1 ± 12.0 years and 50.7% of the cohort was female. During 
a mean follow-up of 8.3 years, 199 subjects (3.1%) were newly diagnosed 
with HF, 456 (7.1%) experienced a CV event and 356 died from all causes. 
A higher annual HF incidence per ferritin quartile was observed in women 
(P < 0.001), but not in men (P for interaction 0.032). Multivariable analyses 
demonstrated ferritin levels to remain independently predictive for new 
onset HF in women only (P = 0.024). This association persisted within strata 
defined by markers of the metabolic syndrome, markers of inflammation 
or other markers of iron homeostasis, including hepcidin. No association 
between ferritin or hepcidin and incident CV events or all-cause mortality 
was observed in either sex.
conclusions:
Increased serum ferritin levels independently amplify the risk for new onset 
HF in women in the community. Studies need to elucidate the pathophysi-




BMI = body mass index
CV = cardiovascular
HF = heart failure
HFpEF = heart failure with preserved ejection fraction
HFrEF = heart failure with reduced ejection fraction
hs-CRP = high-sensitive C-reactive protein
LBBB = left bundle branch block
LVH = left ventricular hypertrophy
MI = myocardial infarction
PREVEND = Prevention of REnal and Vascular ENd-stage Disease
ROS = Reactive oxygen species
TSAT = Transferrin saturation
UAE = urinary albumin excretion
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Iron markers and new onset heart failure in the community
InTroduCTIon
Iron is an essential micronutrient for a wide range of metabolic and bio-
logical processes. Systemic iron homeostasis is orchestrated by hepcidin, 
a liver-derived peptide that has emerged as the key circulating regulator 
of iron absorption and tissue distribution.1 In response to low body iron 
stores, decreased erythropoiesis and hypoxia, hepcidin levels decrease al-
lowing efficient iron mobilization. In contrast, inflammation and increased 
body iron stores cause excessive hepcidin production, which subsequently 
inhibits intestinal iron absorption and iron release from reticuloendothelial 
macrophages.1
In patients with primary and secondary causes of iron overload, cardio-
myopathy is a common manifestation.2 In contrast, severe iron deficiency 
has also been associated with abnormalities in systolic and diastolic cardiac 
function, suggesting an U-shaped relationship between body iron stores 
and the process leading to heart failure.3,4 Prior epidemiological studies 
have proposed an association between increasing body iron stores (mostly 
expressed as serum ferritin levels) and risk for cardiovascular (CV) disease 
in the general population, whereas others have found conflicting results.5 
Likewise, the role of hepcidin as a risk modifier in cardiovascular disease is 
also controversial.6,7
Whether markers of iron status, either depleted or in overload, or regu-
latory hormone hepcidin predict the risk of new onset heart failure (HF) 
among healthy individuals is unknown. Therefore, we aimed to determine 
whether markers of iron homeostasis antedate the development of HF and 
cardiovascular outcome. For these purposes, we used data obtained in the 
Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study, a 
large prospective, well-characterized, contemporary observational cohort 
with a long-term follow-up period.
meThods
This study was performed using data of subjects participating in the PRE-
VEND study. Details of the study protocol have been published elsewhere 
(www.prevend.org).8 In brief, from 1997 to 1998, all inhabitants of the city of 
Groningen, The Netherlands, aged 28-75 years, were sent a questionnaire on 
demographics, disease history, smoking habits, use of medication, and a vial 
to collect an early morning urinary sample (n = 85,421). Of these subjects, 
40,856 responded (47.8%). After exclusion of subjects with type 1 diabetes 
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5mellitus (defined as the use of insulin), and pregnant women, subjects with 
an urinary albumin excretion (UAE) ≥10 mg/L (n=6000) and a randomly 
selected control group with an UAE <10 mg/L (n=2592) completed the pro-
tocol and formed the baseline PREVEND cohort (n=8592). For the current 
analyses we used data from the second survey, which took place between 
2001 and 2003 (n=6894), as hepcidin and iron measurements were only 
available from this time period. We excluded 508 subjects due to missing 
ferritin or hepcidin values, and missing follow-up data, leaving 6386 sub-
jects for the current analysis. The PREVEND study was approved by the 
institutional medical ethics committee and conducted in accordance with 
the Declaration of Helsinki. All subjects provided written informed consent.
definitions & calculations
Blood pressure was calculated as the mean of the measurements of the 
two study visits of the second survey. Hypertension was defined as systolic 
blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg, or self-
reported use of antihypertensive medication. Body mass index (BMI) was 
calculated as the ratio of weight and height squared (kg/m2), and obesity 
was defined as a BMI > 30 kg/m2. Hypercholesterolemia was defined as 
total serum cholesterol > 6.5 mmol/L (251 mg/dL), a serum cholesterol ≥ 
5.0 mmol/L (193mg/dL) when a history of myocardial infarction (MI) was 
present or when lipid-lowering medication was used. Type 2 diabetes 
mellitus was defined as a fasting glucose level of ≥ 7.0 mmol/L (126 mg/
dL), a non-fasting glucose level of ≥ 11.1mmol/L (200 mg/dL), or the use of 
anti-diabetic drugs. Smoking was defined as current smoking or smoking 
cessation within the previous year. Urinary albumin excretion was calcu-
lated as the average UAE in the two consecutive 24-h urine collections. An 
estimate of the glomerular filtration rate was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.9 History 
of myocardial infarction or stroke was defined as a self-reported condition 
requiring hospitalization for at least 3 days. Anemia was defined according 
to the World Health Organization (WHO) criteria (hemoglobin < 13 g/dL for 
men and < 12 g/dL for women).10 Standard 12-lead electrocardiograms were 
recorded using the computer Modular ECG Analysis System.11 The presence 
of a left bundle branch block (LBBB) was defined as a QRS duration on ECG 
>120msec. Left ventricular hypertrophy (LVH) was defined using the Cornell 
criteria: RaVL + SV3 (with 6mm added in women) multiplied by the QRS 
duration. A threshold of 2440 mm*ms was used to identify LVH.12
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analytical methods
Fasting blood samples were obtained in the morning from all participants 
from 2001-2003. Aliquots of these samples were stored immediately 
at -80°C until further analysis. Hemoglobin (g/dL) was measured using 
a Coulter Counter STKS sum (Coulter Corporation, Miami, Florida, USA). 
Serum iron (umol/L), ferritin (ug/L) and transferrin (g/L) were measured 
using a colorimetric assay, immunoassay and immunoturbidimetric assay, 
respectively (Roche Diagnostics, Mannheim, Germany). The total iron bind-
ing capacity was calculated by multiplying transferrin x 25.2. Subsequently, 
transferrin saturation (TSAT [%]) was computed by dividing serum iron by 
TIBC and multiplied by 100. Serum hepcidin concentrations were measured 
with a competitive enzyme-linked immunosorbent assay, as described else-
where.13 The between-plates and inter-assay coefficient of variation (CV) 
were 8.6% and 16.2%, respectively. Hepcidin concentrations are expressed 
in nanomoles per liter (nmol/L). Concentrations of total cholesterol, plasma 
glucose and serum creatinine were measured using standard methods. 
Urinary albumin concentration was determined by nephelometry, with a 
threshold of 2.3 mg/L and intra- and interassay CV of 2.2 and 2.6%, respec-
tively (BN II, Dade Behring Diagnostica, Marburg, Germany). High-sensitive 
C-reactive protein (hs-CRP) was also determined using nephrelometry with 
a threshold of 0.175 mg/L and intra- and interassay coefficients of less than 
4.4 and 5.7% respectively.
definition of cardiovascular events and new onset heart failure
Follow-up for the present study was defined as the time between the first 
follow-up visit to the outpatient department and the date of a CV event, new 
onset HF, death, or January 1st 2011. Subjects were censored on the date they 
moved to an unknown destination or at the last date of follow-up (January 1st 
2011), whichever date came first. Information on dates and causes of death 
for every participant was obtained from Statistics Netherlands and coded 
according to the 10th revision of the International Classification of Diseases.14
The combined incidence of CV morbidity and mortality after the second 
survey was used. Information on hospitalization for CV morbidity was ob-
tained from PRISMANT, the Dutch national registry of hospital discharge 
diagnoses, which has proven validity with 84% of the primary diagnosis and 
87% of the secondary diagnosis matching those recorded in the patients’ 
charts.15 In the present study, CV events were defined as the following: 
acute MI (ICD-code 410), acute and subacute ischaemic heart disease (411), 
subarachnoid haemorrhage (430), intra-cerebral haemorrhage (431), other 
intra-cranial haemorrhage (432), occlusion or stenosis of the pre-cerebral 
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5(433) or cerebral arteries (434), coronary artery bypass grafting or percu-
taneous transluminal coronary angioplasty, and other vascular interventions 
as percutaneous transluminal angioplasty or bypass grafting of aorta and 
peripheral vessels.
Participants with a new diagnosis of HF were identified using criteria 
described in the Heart Failure Guidelines of the European Society of Cardi-
ology and an endpoint adjudication committee ascertained the diagnosis 
of HF, as described elsewhere.16 Additionally, HF was classified as HF with 
a reduced (HFrEF) or preserved ejection fraction (HFpEF) based on the 
left ventricular ejection fraction at the time of diagnosis. To acknowledge 
the most recent trends in cut-off for HFrEF and HFpEF in accordance with 
the most recent HF guidelines, we set the cut-off for HFpEF at ≥ 50%.17 In 
all subjects developing new onset heart failure in the present study data on 
LVEF was available.
Statistical analyses
Baseline continuous variables are expressed as means with standard devia-
tion (SD) when normally distributed, as medians with interquartile range 
(IQR) when distribution is skewed, or as numbers and percentages when 
categorical. Inter-group differences were tested using trend-analyses. For 
further analyses, skewed variables were transformed to a 2-log scale to 
achieve a normal distribution.
By design, the PREVEND study over-selected subjects with an elevated 
UAE (> 10mg/L). To overcome this over-selection of subjects with UAE, a 
statistical weighted method was applied in our regression analyses, allow-
ing our conclusions to be generalized to the general population.18,19 The as-
sociation of ferritin with baseline variables was examined by bootstrapping 
the linear regression model 1000 times. Variables selected >700 times were 
assumed to be accurate and included in the multivariate model.
Overall and sex-stratified adjusted annual incidence rates of new onset 
HF, CV events, and all-cause mortality were assessed assuming a Poisson 
distribution. The test for trend was calculated using the Mantel-Haenszel 
method. To preserve ferritin (and hepcidin) as continuous variables, multi-
variable fractional polynomials were employed to determine the best fitting 
functional form of both markers for all outcome parameters. To account for 
death as a competing risk for new onset HF, a subject’s follow-up time was 
censored at the time of death whenever death occurred before the onset of 
HF. Hazard ratios are then interpreted as the covariate effects on the cause-
specific (sub)hazard function of the transition from heart failure-free to 
new onset HF in a competing risks model with new onset HF and all-cause 
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mortality as the two absorbing states.20 Crude analyses were consecutively 
adjusted for 1) age and sex; 2) a multivariate model consisting of the fol-
lowing established HF and CV risk factors: age, sex, BMI, current smoking, 
diabetes, hypertension, hypercholesterolemia, history of MI or stroke, LVH, 
renal function, and levels of hemoglobin, erythropoietin, UAE, and presence 
of inflammation (hs-CRP>5 mg/L); and 3) time-varying development of CV 
events. Similar analyses were done for incident CV events and all-cause 
mortality. All reported probability values are two-tailed and a value of P < 
0.05 was used as the nominal level of statistical significance. Models and 
analyses were performed using STATA software version 13.0 (StataCorp LP, 
College station, Texas, USA).
resulTs
Baseline characteristics of the 6386 subjects, stratified per ferritin quartiles, 
are displayed in Table 1. Mean age was 53.1 ± 12.0 years and 50.7% of the 
cohort was female. Median ferritin concentration was 97 (47 - 173) ug/L and 
was higher in men (142 ug/L) compared to women (61 ug/L; P < 0.001). Iron 
deficiency, defined by ferritin levels < 30ug/L, was present in 928 subjects 
(14.5%) and more frequently observed in women (24.6% vs. 4.2% in men; 
P < 0.001). Although postmenopausal women had significantly higher fer-
ritin levels in relation to their premenopausal counterparts (94 ug/L vs. 36 
ug/L; P<0.001), iron deficiency was still more frequently seen when com-
pared to men (8.7% vs. 4.2% in men; P < 0.001).
Per increasing ferritin quartile, individuals were generally older, more 
often male, and more likely to have cardiovascular risk factors (e.g. diabetes, 
hypertension). Additionally, higher concentrations of hemoglobin, hs-CRP, 
TSAT and hepcidin were observed, whereas renal function worsened and 
EPO concentrations declined. Baseline ferritin quartiles were addition-
ally stratified by sex (Table S1A&1B). Similar results were detected for both 
sexes, with the exception of prior MI and the presence of either LBBB or 
LVH, which were more frequently observed in women.
clinical associates of ferritin levels
In both sexes, serum ferritin remained positively correlated with hemoglobin 
and MCV, other markers of iron homeostasis and glucose concentrations. 
Whereas ferritin was strongly related to cardiovascular risk factors (BMI, 
cholesterol) in men, inflammation and decreasing erythropoietin levels 
were correlated with ferritin levels in women (Table 2). In a bootstrapped 
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5model for ferritin (per doubling), these variables were highly selected. The 
presence of LVH (a strong HF risk factor) or LBBB was associated with fer-
ritin levels in women (but not in men) in univariable regression only (Table 
S2). The multivariable model in women had a better model fit compared to 
men (Table 2). Similar cardiovascular risk factors related to ferritin levels in 
men and women without prior CV disease and adjusted R2 was comparable 
(Table S3).
markers of iron homeostasis and new onset heart failure.
After a median follow-up of 8.3 (7.8-8.9), years, 199 individuals (3.1%) were 
diagnosed with new onset HF, 456 (7.1%) experienced a CV event and 356 
(5.6%) died from all-causes. Compared to other markers of iron status, ferri-
tin had the best accuracy in predicting incident HF and other events (Figure 
S1). The adjusted annual incidence of new onset HF rose per increasing fer-
figure 1. Total annual incidence of new onset heart failure according to ferritin (1A) and hepcidin 
(1B) quartiles and stratified by sex.
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Iron markers and new onset heart failure in the community
ritin quartile (Figure 1). This trend only appeared to be significant in women 
(P < 0.001). Crude and multivariable fractional polynomials revealed the 
association between ferritin levels and the development of new onset HF 
to be best described by a linear function. In subsequent Cox regression 
analyses (with all-cause mortality as a competing risk) increasing ferritin 
concentrations were strongly associated with the development of new 
onset HF (P < 0.001; Table 3) However, this association was lost in multivari-
able analyses. Interaction analyses showed a significant interaction between 
sex, ferritin levels and new onset HF (Pint  0.032). When stratified by sex, this 
association persisted only in women (P < 0.001) and remained significant 
in all multivariable models. Adjusting for menstrual status did not alter the 
results. No interaction between menstrual status, ferritin levels and develop-
ment of new onset HF was found in women (P = 0.59). Additional subgroup 
analyses in women demonstrated increasing ferritin levels to amplify risk for 
incident HF in almost every subgroup, but were significantly more predic-
tive in women without anemia, without microalbuminuria and with an eGFR 
>60 ml/min/1.73m2.(Figure S2).
Since body iron stores are firmly regulated at the systemic level by hep-
cidin, we additionally explored the role of hepcidin and risk of new onset HF. 
Similar observations regarding adjusted annual HF incidence were made for 
hepcidin, both overall and in women (Figure 1). Likewise, a strong associa-
Table 2. Multivariable regression beta-coefficients between cardiovasular risk factors and serum 
ferritin in men and women (selected after bootstrapping).










T P - 
value
standardized ß T P - 
value
Menstruation (yes vs. no) - - - −0.129 −7.4 < 0.001
BMI (per kg/m2) 0.090 5.4 < 0.001 - - -
Smoking (yes vs. no) - - - −0.035 −2.6 0.011
Hemoglobin (per g/dL) 0.108 6.5 < 0.001 0.071 4.1 < 0.001
MCV (per fL) 0.099 6.0 < 0.001 0.124 7.6 < 0.001
Log 2 hepcidin (nmol/L) 0.680 38.6 < 0.001 0.625 30.4 < 0.001
TSAT (per 5%) 0.094 5.1 < 0.001 0.131 5.7 < 0.001
Log 2 erythropoietin 
(IU/L)
- - - −0.031 −2.0 0.042
Log 2 hs-CRP (mg/L)) - - - 0.059 3.5 < 0.001
Cholesterol (mmol/L) 0.044 2.5 0.011 - - -
Log 2 glucose (mmol/L) 0.043 3.6 < 0.001 0.052 4.4 < 0.001
  r2 total model 0.60 r2 total model 0.74
For abbreviations, see Table 1.
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5Table 3. Levels of ferritin and hepcidin and risk for incident heart failure with all-cause mortality 
as a competing risk.
ferritin (per doubling)   shr 95%CI harrell’s C P-value
Total population (n = 6386)1
 Univariable 1.48 1.30–1.69 0.64 < 0.001
 Model 1 1.24 1.05–1.46 0.83 0.011
 Model 2 1.06 0.89 – 1.26 0.88 0.45
men (n = 3145)
 Univariable 1.00 0.81–1.23 0.52 0.98
 Model 1 1.06 0.87–1.29 0.82 0.54
 Model 2 0.92 0.75–1.14 0.87 0.45
Women (n = 3241)
 Univariable 2.07 1.63–2.61 0.74 < 0.001
 Model 1 1.57 1.20–2.05 0.83 0.001
 Model 1A 1.69 1.26–2.26 0.79  < 0.001
 Model 2 1.35 1.02–1.79 0.87 0.038
 Model 3 1.39 1.05–1.86 0.87 0.024
hepcidin (per doubling) hr 95%CI harrell’s C P-value
Total population (n = 6386)2
 Univariable 1.45 1.23–1.72 0.61 < 0.001
 Model 1 1.20 0.98–1.45 0.83 0.07
 Model 2 1.09 0.92–1.30 0.88 0.39
men (n = 3145)
 Univariable 0.96 0.79–1.16 0.54 0.76
 Model 1 1.00 0.81–1.25 0.82 0.94
 Model 2 0.95 0.74–1.21 0.87 0.49
Women (n = 3241)
 Univariable 2.10 1.63–2.70 0.75 < 0.001
 Model 1 1.59 1.17–2.17 0.84 0.003
 Model 1A 1.68 1.19–2.37 0.79  0.003
 Model 2 1.44 1.03–2.05 0.87 0.039
 Model 3 1.60 1.09–2.37 0.88 0.018
Abbreviations: CI = Confidence interval, sHR = Sub-hazard ratio.
1P for interaction ferritin, sex and new onset heart failure = 0.032.
2P for interaction hepcidin, sex and new onset heart failure = 0.045.
Model 1 is adjusted for age (per 10 years) and sex (in total population).
Model 1A is adjusted for menstrual state instead of age.
Model 2 is adjusted for model 1 + cardiovascular and heart failure risk factors: BMI, current smoking, the presence 
of diabetes, hypertension, hypercholesterolemia, history of MI or stroke, LVH, renal function, and levels of hemo-
globin, erythropoietin, hs-CRP and UAE.
Model 3 is adjusted for model 2 + time-varying incident cardiovascular events.
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5tion between levels of hepcidin and the development of new onset heart 
failure was observed in women only (Pint 0.045). Removing potential outli-
ers (highest and lowest 1%) did not change the results. In subjects without 
prior myocardial infarction and/or stroke, both ferritin and hepcidin levels 
remained strongly associated with the development of HF in women (Table 
S4). Sensitivity analyses in postmenopausal women showed ferritin - and 
not hepcidin - to remain predictive for new-onset HF (Table S5).
To assess whether the association between body iron stores and risk of 
new onset HF were modified by other markers of iron homeostasis (TSAT, 
hepcidin), inflammation (hs-CRP) or the metabolic syndrome (BMI, glucose, 
systolic blood pressure), the joint association of ferritin levels with either 
one of these 6 variables and the development of HF was examined. In these 
joint analyses, ferritin levels remained independently associated with new 
onset HF in women in almost all stratified analyses.(Figure 2).
Finally, 79 of the 199 subjects newly diagnosed with HF were women. 
Of these women, 37 developed HFrEF and 42 HFpEF. Unadjusted cause-
specific hazard analyses demonstrated serum ferritin to be associated with 
either HFrEF or HFpEF, with no significant interaction between both entities 
(Table S6). Multivariable analyses showed that levels of ferritin remained 
strongly associated with an increased risk for HFpEF only. However, again 
no significant interaction was found.
markers of iron homeostasis and risk for cardiovascular disease 
and all-cause mortality.
A higher total annual incidence of new CV events and all-cause mortality 
was observed per increasing ferritin and hepcidin quartile (Figure S3). When 
stratified by sex, these observations only persisted in women. Multivariable 
fractional polynomials again showed the best fitting functional form be-
tween levels of ferritin or hepcidin and new CV events to be linear. Crude 
regression analyses showed increasing ferritin and hepcidin concentrations 
to be both strongly predictive for new CV events and all-cause mortality in 
the overall population and in women (both P < 0.001). However, age- and 
multivariable analyses were non-significant. No interaction between vari-
ables was demonstrated.
dIsCussIon
In this contemporary, prospective, population-based cohort, increasing 
ferritin levels amplify the risk for new onset HF in women, but not in men. 
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This relationship is independent of established conventional CV and HF risk 
factors and the development of CV events over time. These observations 
provide evidence that increased ferritin levels are an independent risk factor 
for the development of HF in women and might play a direct or indirect role 
in the pathogenic mechanism leading to HF.
How do elevated iron stores relate to incident heart failure?
Whereas iron deficiency has detrimental effects on outcome in established 
heart failure,17,21,22 the role of iron markers or markers of erythropoiesis in the 
development of HF has only been investigated to some extent.23,24 Previous 
literature suggested a U-shaped relationship between iron stores and new 
onset HF.3,4.In the present study, we observed a linear relationship between 
increasing ferritin levels and the development of HF. Excess body iron is 
known to accumulate in organs such as the heart and lead to cardiomy-
opathy. The generation of reactive oxygen species (ROS) in mitochondria 
is believed to be the most important pathogenic pathway determining 
cardiomyocyte damage. Production of ROS causes lipid peroxidation and 
DNA damage, leading to cell death, fibrosis, and eventually cardiac dysfunc-
tion. However, iron overload is only observed when the binding capacity of 
transferrin is fully saturated and non-transferrin bound iron is formed. Inter-
estingly, joint analyses showed an association between serum ferritin and 
new onset HF in all TSAT tertiles, suggesting that another pathway linking 
increased ferritin levels with cardiomyocyte damage may also be involved.
Iron-mediated cell damage does not only occur under conditions of iron 
overload. It has been proposed that iron maldistribution among organs, 
tissues and cellular compartments can also attenuate cell integrity and cell 
life. Dysmetabolic hyperferritinemia, meaning elevated ferritin levels with 
normal TSAT, is commonly observed in clinical practice and has been associ-
ated with insulin resistance, obesity, hypertension, and other manifestations 
of the metabolic syndrome.25 During circumstances of subclinical systemic 
inflammation, iron efflux in organs may be halted due to increased hepcidin 
production and subsequent internalization and degradation of its receptor, 
iron exporter ferroportin.26 Therefore, elevated ferritin levels (and hepcidin) 
might be a reflection to a low-grade inflammatory response of another 
pathophysiological process (e.g. metabolic syndrome), causally responsible 
for the development of HF.27 Supporting this hypothesis is the fact that we 
observed a positive trend in blood pressure, BMI, and levels of glucose, 
cholesterol and hs-CRP per increasing ferritin quartile. Additionally, strong 
associations between ferritin and levels of hepcidin, hs-CRP, and glucose in 
women were observed. To minimize for potential confounding, we adjusted 
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5for the presence of obesity, diabetes, hypertension, hypercholesterolemia 
and inflammation in our multivariable analyses. Moreover, joint analyses 
showed increasing ferritin levels to remain predictive for incident HF in 
almost all tertiles. Nevertheless, to which extent elevated ferritin levels truly 
reflect iron stores (inflammation and oxidative stress may complicate the 
picture) is unclear. Moreover, the exact mechanism linking increased ferritin 
levels, iron-regulatory hormone hepcidin and the development of HF is still 
not completely understood.
To our surprise, the association between increasing ferritin levels and 
new onset HF was only present in women. It is known that some traditional 
cardiovascular risk factors may have a different impact on males compared 
to females.28 Additional literature also suggests that the link between 
ferritin, hepcidin and dysmetabolic features may be particularly relevant 
in women.29,30 The role of sex hormones in the regulation of ferritin and 
hepcidin expression may also be responsible to a certain extent for the sex-
related differences observed in the present study and has recently been 
studied in animal models.31 Yet, although we adjusted for menopausal status 
and other established cardiovascular/metabolic risk factors, levels of ferritin 
remained associated with incident HF in women.
Finally, a stronger association between levels of ferritin and the develop-
ment of HFpEF was observed in women. To date there is a limited under-
standing of the underlying pathophysiology of HFpEF. A novel concept in 
the pathogenesis of HFpEF was proposed involving the role of comorbidi-
ties (e.g. hypertension, diabetes) to induce a subclinical inflammatory state, 
eventually leading to microvascular endothelial inflammation and subse-
quent stiffening and diastolic dysfunction.32 Given the aforementioned 
relationship between dysmetabolic hyperferritinemia and diabetes or 
metabolic syndrome, iron misdistribution and consecutive oxidative stress 
might play a direct or indirect role in the development of HFpEF. However, 
no significant interaction between both HF entities was observed and the 
number of HFpEF cases in the present study is low. Therefore, these results 
need cautious interpretation and merit further investigation.
markers of iron status and risk of cardiovascular events
In the present study, we did not observe an association between ferritin or 
hepcidin concentrations and development of CV events or all-cause mortal-
ity in multivariable analyses. It has been hypothesized that both elevated 
and decreased markers of iron status enhance the risk for CV disease33,34. 
However, conflicting results have also been reported.35 Furthermore, stud-
ies in hemodialysis patients or women from the general population have 
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suggested a role for elevated hepcidin levels in the pathogenesis of athero-
sclerosis.36-38 In contrast, Kautz and colleagues did not detect any increase 
in hepatic hepcidin expression during progression of atherosclerosis or ath-
erosclerotic plaque size in mice with elevated macrophage iron.6 A recently 
published population-based study also found no relationship between hep-
cidin or hepcidin-to-ferritin ratio and prevalent carotid atherosclerosis or 
incident CV events.7 Future population-based studies are needed to finally 
establish whether an abnormal iron homeostasis is associated with the de-
velopment of CV events in the general population.
Implications for clinical practice
Although the present associations do not prove causality between iron 
stores and incident HF, the present study provides evidence that increased 
ferritin levels may directly or indirectly be associated with the pathogenesis 
of new onset HF in women. Identification of subjects at risk for HF using 
biomarkers alongside clinical characteristics has grown interest over the 
years. Markers of iron homeostasis may provide additional information to 
the clinician regarding etiology, clinical risk (in our case heart failure) and 
disease severity. Secondly, ferritin is a widely available routine marker and a 
relatively inexpensive measurement. Finally, elimination of iron may confer a 
beneficial effect. Iron removal, by means of phlebotomy, improved coronary 
vascular function in patients with type 2 diabetes and endothelial function 
in patients with known coronary artery disease.39,40 Still, the findings of this 
study need to be validated in other population-based studies.
Strengths and limitations
The large size of this contemporary, prospective community-based cohort, 
long follow-up period, and thorough validation of outcome parameters, are 
strengths of this study. Furthermore, all blood samples were taken in the 
morning, minimizing the influence of circadian rhythm on markers of iron 
status. The present study is limited by the fact that the subjects from the 
PREVEND study are predominantly Caucasian and our results can therefore 
not be extrapolated to subjects from other ethnicities. Second, our analyses 
rely on one baseline measurement of iron markers and hepcidin, which is used 
as a proxy for the concentration in the years before and after this measure-
ment. Therefore, we can’t comment on the effects of changes in markers over 
time. More population-based studies with serial measurements over time are 
warranted. Third, long-term storage at −80° Celsius might be associated, to 
some extend, with less precise measurements of hepcidin. A recent paper by 
Laarakkers and coworkers investigated the stability of hepcidin during long-
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5term storage.41 The authors concluded that hepcidin results are not changed 
during 2 years of storage at −80° Celsius. However, after 2 years storage at 
−80°Celsius, hepcidin results may become less precise. Although we believe 
that average results for a population may not be affected, perhaps existing 
differences in hepcidin levels between groups, or correlations of hepcidin with 
other parameters might be more difficult to assess. Finally, the PREVEND 
cohort is enriched for increased UAE. For this reason, we corrected for study 
design by conducting a design-based analysis. Furthermore, compared with 
the Framingham cohort, UAE was not higher in PREVEND.42
ConClusIons
In conclusion, increased ferritin levels independently enhance the risk 
for new onset heart failure in apparently healthy women. These findings 
provide evidence that elevated ferritin concentrations may be directly or 
indirectly involved in the pathogenesis of new onset HF in women in the 
community. Studies need to elucidate the pathophysiological mechanisms 
through which ferritin levels associate with specific outcomes.
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Iron markers and new onset heart failure in the community
Table s3. Multivariable regression beta-coefficients between cardiovascular risk factors and 
serum ferritin in men and women without prior myocardial infarction and/or stroke (selected 
after bootstrapping).
variables
men (n = 2969) Women (n = 3178) 
standardized ß T P - value standardized ß T P - value
Menstruation (yes vs. no) - - - −0.127 −7.2 < 0.001
BMI (per kg/m2) 0.086 5.0 < 0.001 - - -
Smoking - - - −0.030 −2.2 0.028
Hemoglobin (per g/dL) 0.106 6.1 < 0.001 0.071 4.0 < 0.001
MCV (per fL) 0.097 5.6 < 0.001 0.122 7.4  < 0.001
Log 2 ferritin (ug/L) 0.679 37.4 < 0.001 0.728 30.4 < 0.001
TSAT (per 5%) 0.094 4.8 < 0.001 0.016 5.9 < 0.001
Log 2 erythropoietin 
(IU/L)
- - - −0.064 −3.9 0.044
Cholesterol (per mmol/L) 0.045 2.51 0.012 - - -
Log 2 hs-CRP (mg/L)) - - - 0.079 5.4 < 0.001
Log 2 glucose (mmol/L) 0.015 0.9 0.001 0.053 4.8 < 0.001
   r2 total model 0.59  r2 total model 0.75
For abbreviations, see Table 1.
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5Table s4. Ferritin and hepcidin levels and incident heart failure with death as competing risk in 
subjects without prior myocardial infarction and/or stroke.
ferritin (per doubling) shr 95% CI P - value
Total population (n = 6147)1
 Unadjusted 1.49 1.28–1.74 < 0.001
 Model 1 1.30 1.07–1.56 0.007
 Model 2 1.09 0.91–1.32 0.345
men (n = 2969)
 Unadjusted 1.06 0.81–1.38 0.678
 Model 1 1.06 0.83–1.34 0.657
 Model 2 0.89 0.68–1.15 0.359
Women (n = 3178)
 Unadjusted 2.04 1.61–2.59 < 0.001
 Model 1 1.54 1.19–2.00 0.001
 Model 1A 1.71 1.28–2.27  < 0.001
 Model 2 1.32 1.03–1.71 0.033
 Model 3 1.33 1.05–1.85 0.026
hepcidin (per doubling) shr 95% CI P - value
Total population (n = 6147)2
 Unadjusted 1.57 1.32–1.87 < 0.001
 Model 1 1.29 1.05–1.58 0.012
 Model 2 1.11 0.92–1.36 0.259
men (n = 2969)
 Unadjusted 1.09 0.82–1.42 0.598
 Model 1 1.05 0.82–1.35 0.695
 Model 2 0.90 0.72–1.11 0.321
Women (n = 3178)
 Unadjusted 2.09 1.64–2.68 < 0.001
 Model 1 1.60 1.19–2.15 0.002
 Model 1A 1.73 1.23–2.45  0.002
 Model 2 1.41 1.04–1.90 0.027
 Model 3 1.41 1.07–2.23 0.019
Abbreviations: CI = Confidence interval, sHR = Sub-hazard ratio.
1P for interaction ferritin, sex and new onset heart failure = 0.046.
2P for interaction hepcidin, sex and new onset heart failure = 0.034.
Model 1 is adjusted for age (per 10 years).
Model 1A is adjusted for menstrual state instead of age.
Model 2 is adjusted for model 1 + cardiovascular and heart failure risk factors: BMI, current smoking, the presence 
of diabetes, hypertension, hypercholesterolemia, LVH, renal function, and levels of hemoglobin, erythropoietin, 
hs-CRP and UAE.
Model 3 is adjusted for model 2 + time-varying incident cardiovascular events.
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Table s5. Hepcidin and ferritin levels and incident heart failure with death as competing risk in 
postmenopausal women.
Postmenopausal women shr 95% CI P - value
Ferritin (per doubling)      
 Unadjusted 1.75 1.29–2.36 < 0.001
 Model 1 1.57 1.18–2.09 0.002
 Model 2 1.34 1.03–1.78 0.040
 Model 3 1.30 1.02–1.69 0.043
Hepcidin (per doubling)      
 Unadjusted 1.64 1.15–2.35 0.008
 Model 1 1.52 1.08–2.12 0.017
 Model 2 1.31 0.95–1.83 0.10
 Model 3 1.48 0.99–2.21 0.06
Abbreviations: CI = Confidence interval, sHR = Sub-hazard ratio.
Model 1 is adjusted for age (per 10 years).
Model 2 is adjusted for model 1 + cardiovascular and heart failure risk factors: BMI, current smoking, the presence 
of diabetes, hypertension, hypercholesterolemia, history of MI or stroke, LVH, renal function, and levels of hemo-
globin, erythropoietin, hs-CRP and UAE.
Model 3 is adjusted for model 2 + time-varying incident cardiovascular events.
Table s6. Levels of ferritin and cause-specific risk for heart failure with a reduced or preserved 
ejection fraction in women.
ferritin (per doubling)   hr 95% CI P - value P - int
hfref (n = 37)  
 Unadjusted 1.96 1.55 – 2.48 < 0.001 0.28
 Model 1 1.48 1.14 – 1.90 0.003 0.28
 Model 2 1.25 0.97 – 1.62 0.09 0.17
 Model 3 1.27 0.98 – 1.64 0.07 0.17
hfpef (n = 42)
 Unadjusted 2.06 1.64 – 2.59 < 0.001 NA
 Model 1 1.55 1.21 – 2.00 0.001 NA
 Model 2 1.34 1.04 – 1.71 0.022 NA
 Model 3     1.36 1.06 – 1.73 0.013 NA
Abbreviations: CI = Confidence interval, HR = Hazard ratio, NA = Not applicable.
Model 1 is adjusted for age (per 10 years).
Model 2 is adjusted for model 1 + cardiovascular and heart failure risk factors: BMI, current smoking, the presence 
of diabetes, hypertension, hypercholesterolemia, history of MI or stroke, LVH, renal function, and levels of hemo-
globin, erythropoietin, hs-CRP and UAE.






















































































































Iron markers and new onset heart failure in the community
figure s2. Ferritin levels and risk for new onset heart failure among subgroups in women.
figure s3. Total annual incidence of cardiovascular events (A + B) and all-cause mortality (C + 
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